Influenza A Virus Vaccines Containing Purified Recombinant H3 Hemagglutinin Are Well Tolerated and Induce Protective Immune Responses in Healthy Adults

摘要: This study evaluated the safety, immunogenicity, and protective efficacy of vaccines containing purified recombinant uncleaved hemagglutinin (rHA0) from influenza A/Beijing/32/92 (H3N2) virus. In a randomized, double-blinded trial, 127 adult volunteers were immunized with 15 micrograms rHA0, rHA0 plus alum, 90 licensed subvirion vaccine, or saline placebo. The caused fewer local adverse reactions than did commercial preparation. Neutralizing hemagglutinin-specific antibody responses to comparable those elicited by not enhanced addition significantly increased raising dose micrograms. Compared placebo recipients, rHA0-vaccinated subjects had lower rates A virus infection illness during epidemic winter season. These results suggest that may offer an advantage over preparations egg-grown antigens inducing equivalent immune while being potentially less reactogenic.